Advanced Biomedical Research

Optimization of the Expression of DT386-BR2 Fusion Protein in Escherichia coli using Response Surface Methodology

Document Type : Original Article

Authors

1 Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan; Bioinformatics Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: The aim of this study was to determine the best condition for the production of DT386-BR2 fusion protein, an immunotoxin consisting of catalytic and translocation domains of diphtheria toxin fused to BR2, a cancer specific cell penetrating peptide, for targeted eradication of cancer cells, in terms of the host, cultivation condition, and culture medium. Materials and Methods: Recombinant pET28a vector containing the codons optimized for the expression of the DT386-BR2 gene was transformed to different strains of Escherichia coli (E. coli BL21 DE3, E. coli Rosetta DE3 and E. coli Rosetta-gami 2 DE3), followed by the induction of expression using 1 mM IPTG. Then, the strain with the highest ability to produce recombinant protein was selected and used to determine the best expression condition using response surface methodology (RSM). Finally, the best culture medium was selected. Results: Densitometry analysis of sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the expressed fusion protein showed that E. coli Rosetta DE3 produced the highest amounts of the recombinant fusion protein when quantified by 1 mg/ml bovine serum albumin (178.07 μg/ml). Results of RSM also showed the best condition for the production of the recombinant fusion protein was induction with 1 mM IPTG for 2 h at 37°C. Finally, it was established that terrific broth could produce higher amounts of the fusion protein when compared to other culture media. Conclusion: In this study, we expressed the recombinant DT386-BR2 fusion protein in large amounts by optimizing the expression host, cultivation condition, and culture medium. This fusion protein will be subjected to purification and evaluation of its cytotoxic effects in future studies.

Keywords

1.
Makino T, Skretas G, Georgiou G. Strain engineering for improved expression of recombinant proteins in bacteria. Microb Cell Fact 2011;10:32.  Back to cited text no. 1
    
2.
Czitrom V. One-factor-at-a-time versus designed experiments. Am Stat 1999;53:126-31.  Back to cited text no. 2
    
3.
Araujo PW, Brereton RG. Experimental design II. Optimization. Trends Analyt Chem 1996;15:63-70.  Back to cited text no. 3
    
4.
Bezerra MA, Santelli RE, Oliveira EP, Villar LS, Escaleira LA. Response surface methodology (RSM) as a tool for optimization in analytical chemistry. Talanta 2008;76:965-77.  Back to cited text no. 4
    
5.
Myers RH, Montgomery DC, Anderson-Cook CM. Response Surface Methodology: Process and Product Optimization Using Designed Experiments 3rd edithion: John Wiley and Sons; 2016.  Back to cited text no. 5
    
6.
Reiter Y. Recombinant immunotoxins in targeted cancer cell therapy. Adv Cancer Res 2001;81:93-124.  Back to cited text no. 6
    
7.
Pushpanathan M, Gunasekaran P, Rajendhran J. Antimicrobial peptides: Versatile biological properties. Int J Pept 2013;2013:675391.  Back to cited text no. 7
    
8.
Martín I, Teixidó M, Giralt E. Building cell selectivity into CPP-mediated strategies. Pharmaceuticals 2010;3:1456-90.  Back to cited text no. 8
    
9.
Black JH, McCubrey JA, Willingham MC, Ramage J, Hogge DE, Frankel AE. Diphtheria toxin-interleukin-3 fusion protein (DT (388) IL3) prolongs disease-free survival of leukemic immunocompromised mice. Leukemia 2003;17:155-9.  Back to cited text no. 9
    
10.
Frankel AE, Powell BL, Hall PD, Case LD, Kreitman RJ. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res 2002;8:1004-13.  Back to cited text no. 10
    
11.
Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 2003;65:3-13.  Back to cited text no. 11
    
12.
Woo JH, Lee YJ, Neville DM, Frankel AE. Pharmacology of Anti-CD3 Diphtheria Immunotoxin in CD3 Positive T-Cell Lymphoma Trials. Immunotherapy of Cancer. Methods Mol Biol: Springer; 2010. p. 157-75.  Back to cited text no. 12
    
13.
Yang X, Kessler E, Su LJ, Thorburn A, Frankel AE, Li Y, et al. Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. Clin Cancer Res 2013;19:148-57.  Back to cited text no. 13
    
14.
Shafiee F, Rabbani M, Jahanian-Najafabadi A. Production and evaluation of cytotoxic effects of DT386-BR2 fusion protein as a novel anti-cancer agent. J microbial meth 2016. In press.  Back to cited text no. 14
    
15.
Sambrook J, Russell DW, Russell DW. The Condensed Protocols from Molecular Cloning: A Laboratory Manual. New York: Cold Spring Harbor Laboratory Press Cold Spring Harbor; 2006.  Back to cited text no. 15
    
16.
Akbari V, Sadeghi HM, Jafarian-Dehkordi A, Chou CP, Abedi D. Optimization of a single-chain antibody fragment overexpression in Escherichia coli using response surface methodology. Res Pharm Sci 2015;10:75-83.  Back to cited text no. 16
    
17.
Shafiee F, Moazen F, Rabbani M, Mir Mohammad Sadeghi H. Optimization of the Expression of Reteplase in Escherichia coli TOP10 using arabinose promoter. Jundishapur J Nat Pharm Prod 2015;10:e16676.  Back to cited text no. 17
    
18.
Rosano GL, Ceccarelli EA. Recombinant protein expression in Escherichia coli: Advances and challenges. In: Recombinant Protein Expression in Microbial Systems; Front Microbiol; 2014. p. 7.  Back to cited text no. 18
    
19.
Zhang Y, Schulte W, Pink D, Phipps K, Zijlstra A, Lewis JD, et al. Sensitivity of cancer cells to truncated diphtheria toxin. PLoS One 2010;5:e10498.  Back to cited text no. 19
    
20.
Liu Y, Wangn J, Qu J, Wang C, Hong T. Cloning and expression of recombinant chimeric toxin DT_(389)-IL-2 and testing of its specific cytotoxicity toward cells which bearing high affinity IL-2 receptor. Chin J Virol 2000;17:117-21.  Back to cited text no. 20
    
21.
Frankel AE, McCubrey JA, Miller MS, Delatte S, Ramage J, Kiser M, et al. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia 2000;14:576-85.  Back to cited text no. 21
    
22.
Gottesman S. Proteases and their targets in Escherichia coli. Annu Rev Genet 1996;30:465-506.  Back to cited text no. 22
    
23.
Grodberg J, Dunn JJ. ompT encodes the Escherichia coli outer membrane protease that cleaves T7 RNA polymerase during purification. J Bacteriol 1988;170:1245-53.  Back to cited text no. 23
    
24.
Studier FW, Moffatt BA. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol 1986;189:113-30.  Back to cited text no. 24
    
25.
Kane JF. Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli. Curr Opin Biotechnol 1995;6:494-500.  Back to cited text no. 25
    
26.
Gopal GJ, Kumar A. Strategies for the production of recombinant protein in Escherichia coli. Protein J 2013;32:419-25.  Back to cited text no. 26
    
27.
Tegel H, Tourle S, Ottosson J, Persson A. Increased levels of recombinant human proteins with the Escherichia coli strain Rosetta (DE3). Protein Expr Purif 2010;69:159-67.  Back to cited text no. 27
    
28.
Bukhtiyarova M, Northrop K, Chai X, Casper D, Karpusas M, Springman E. Improved expression, purification, and crystallization of p38alpha MAP kinase. Protein Expr Purif 2004;37:154-61.  Back to cited text no. 28
    
29.
Vasina JA, Baneyx F. Expression of aggregation-prone recombinant proteins at low temperatures: A comparative study of the Escherichia coli cspA and tac promoter systems. Protein Expr Purif 1997;9:211-8.  Back to cited text no. 29
    
30.
Mosrati R, Nancib N, Boudrant J. Variation and modeling of the probability of plasmid loss as a function of growth rate of plasmid-bearing cells of Escherichia coli during continuous cultures. Biotechnol Bioeng 1993;41:395-404.  Back to cited text no. 30
    
31.
Papaneophytou CP, Kontopidis G. Statistical approaches to maximize recombinant protein expression in Escherichia coli: A general review. Protein Expr Purif 2014;94:22-32.  Back to cited text no. 31
    
32.
Ramirez O, Zamora R, Espinosa G, Merino E, Bolivar F, Quintero R. Kinetic study of penicillin acylase production by recombinant E. coli in batch cultures. Process Biochem 1994;29:197-206.  Back to cited text no. 32
    
33.
Atlas RM. Handbook of Microbiological Media. 4th edition: CRC Press; 2010.  Back to cited text no. 33
    
34.
Blommel PG, Becker KJ, Duvnjak P, Fox BG. Enhanced bacterial protein expression during auto-induction obtained by alteration of lac repressor dosage and medium composition. Biotechnol Prog 2007;23:585-98.  Back to cited text no. 34
    
35.
Sezonov G, Joseleau-Petit D, D'Ari R. Escherichia coli physiology in Luria-Bertani broth. J Bacteriol 2007;189:8746-9.  Back to cited text no. 35
    
36.
Studier FW. Protein production by auto-induction in high density shaking cultures. Protein Expr Purif 2005;41:207-34.  Back to cited text no. 36
    
37.
Litterer L, Schagat T. Protein expression in less time: A short induction protocol for KRX. Promega Notes 2007;96:20-1.  Back to cited text no. 37
    
38.
Li JF, Zhang J, Song R, Zhang JX, Shen Y, Zhang SQ. Production of a cytotoxic cationic antibacterial peptide in Escherichia coli using SUMO fusion partner. Appl Microbiol Biotechnol 2009;84:383-8.  Back to cited text no. 38
Advanced Biomedical Research
Volume 2017, March
March 2017
Pages 1-6